Patients with head-and neck cancer are often treated with radiation therapy. A side-effect to this life saving therapy is reduced salivary production which has serious consequences for mouth-, and dental health and quality of life.

Injection of ASCs directly into the salivary glands in a phase I clinical trial has proven safety and promising efficacy. The first of 120 planned patients were enrolled and treated with ASCs October 2020 in a double-blind placebo-controlled phase II trial in patients suffering from damaged salivary glands due to radiation-induced hyposalivation and xerostomia.